|
|
Article: Barbeau Pharma Announces That Its Studies Of The Cardiotoxicity Of Drug Metabolites Are Consistent With Newly Issued FDA Recommendations For Assessing Pharmaceutical Cardiac Risk.
- Article from:
- Business Wire
- Article date:
- November 22, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NORTHFIELD, Ill. -- Barbeau Pharma, Inc. (BPI), a specialty pharmaceutical company focused on proprietary technologies to transform today's problem drugs into differentiated value-added medicines, announces that its studies of the cardiotoxicity of drug metabolites are consistent with the Food and Drug Administration's (FDA's) newly published guidelines for cardiac risk assessment of human pharmaceuticals.
The Company recently coauthored a presentation at the 5th Annual Meeting of the Safety Pharmacology Society held in Mannheim, Germany that described 1) considerable proarrhythmic activity of hydroxylated (oxidized) imipramine metabolites in contrast to low ...
Related newspaper, magazine, and journal articles:
|
|
Article: FDA grants orphan drug status to Hydralazine.
Biotech Week;
May 26, 2004 ;
700+ words
... ... morbidity and mortality. ESP Pharma, in collaboration with Barbeau Pharma, Inc., (Northfield, Illinois), has been actively ... formulation of intravenous hydralazine, are licensed from Barbeau Pharma.. Spitznagel concluded, "Moreover, the successful pursuit ...
|
|